Novelix has established a high-profile and hands-on Scientific Advisory Board (SAB). The SAB will help guide scientific, regulatory and strategic decisions as they relate to the company's drug development program. The current members are the following four internationally recognized cancer drug development experts.
-
Marcel Bally, PhD (Vancouver, BC, Canada) is a serial entrepreneur in developmental therapeutics and drug delivery. Dr. Bally is the head of Advanced Therapeutics at the British Columbia Cancer Research Centre.
-
Victor J. Bauer, PhD (Somerset, NJ, USA) has 45 years of experience in the pharmaceutical industry. After ten years as a Research Chemist at Lederle Laboratories, he joined Hoechst-Roussel Pharmaceuticals in 1972 as Director of Chemistry Research. Dr. Bauer then served as Vice-President Operations, and retired in 1992 as President. He is an expert on both human and animal drug development. Dr. Bauer is a Co-Founder and Director of Titan Pharmaceuticals, Inc. Dr. Bauer received an SB from MIT, a PhD from the University of Wisconsin and was a Research Fellow in Chemistry at Harvard University.
-
Shoukat Dedhar, Ph.D. (Vancouver, BC, Canada) is one of the world’s foremost experts on integrin signaling and function and helps guide Novelix’ small molecule αvβ3 integrin drug development program. Dr. Dedhar is a Professor in the Department of Biochemistry and Molecular Biology at the University of British Columbia and a Senior Investigator at the British Columbia Cancer Agency.
-
Howard Fingert, MD (Quaker Hill, CT, USA) is a Harvard-trained oncologist-hematologist with over 10 years of pharmaceutical industry experience. His experience spans Phases 1-3 clinical development, multiple NDA submissions and FDA approvals of oncology products which have achieved annual sales exceeding $1 billion. Dr. Fingert has had leadership roles in clinical development, regulatory affairs, drug safety and product licensing in biotechnology companies and at one of the world's largest pharmaceuticals companies.
-
Yoel Kloog, PhD (Tel Aviv, Israel) is a well recognized international expert in medicinal chemistry and the development of targeted cancer drugs. Dr. Kloog currently serves as Dean of Life Sciences, Tel Aviv University.
-
Jason Rivers, BSc, MD, FRCPC (Vancouver, BC, Canada) is an internationally recognized professor and opinion leader in cosmetic dermatology and skin cancer prevention. As principal at Vancouver’s Pacific Dermaesthetics, Dr. Rivers has built an internationally recognized practice in cosmetic medicine. His world-class facility is one of the largest and most technologically advanced skin treatment centers in North America. He is the founder of Riversol Skin Care Inc. This plant derived skin care product line offers a powerful anti-oxidant with therapeutic properties, ideally suited for reducing the look of wear and tear on the skin. Dr. Rivers also serves as the current Editor in Chief of the Journal of Cutaneous Medicine and Surgery.
-
Edgar Selzer, MD (Vienna, Austria) is a co-inventor of our lead compound NVX-207 and a driving force behind the development of NVX-188 and related compounds for non-cancer indications through Novelix’ European affiliate. Dr. Selzer has extensive pharmacology experience and is a Professor of Clinical and Experimental Oncology at the Medical University of Vienna.